Given the potential scale of CYP2C19 testing recommended by NICE and considering the acute nature of most stroke admissions, with a clear time pressure to commence definitive antiplatelet therapy, this represents a major unmet need. This evidence concerns the gene CYP2C19 and stroke disorder.